Persistent physical symptoms accompanied by anxiety and/or depressive symptoms Signs and Symptoms
Conditions
Interventions
Current intervention as of 11/10/2022:
During recruitment, health care workers of participating primary health care clinic will refer patients to the study if there is a suspicion of persistent physic
Sponsors
Reykjavík University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Current inclusion criteria as of 11/10/2022: 1. Referred to the study by primary care professionals between January 2022 and October 2022 2. Experience persistent physical symptoms that influence impairment in everyday life 3. Scoring above threshold on one of the following psychological measures: PHQ-9, GAD-7 or SHAI 4. Aged over 18 years of age 5. At assessment, say they will accept psychological treatment of their symptoms _____ Previous inclusion criteria: 1. Referred to VIRK for work rehabilitation between September 2021 and December 2022 2. Experience persistent physical symptoms which influence their workability 3. Scoring above threshold on one of the following psychological measures, PHQ-9, GAD-7 or SHAI 4. Over 18 years of age 5. At assessment, say they will accept psychological treatment of their symptoms
Exclusion criteria
Exclusion criteria: 1. Do not speak/read Icelandic 2. Serious physical or mental health problems that affect participation in treatment, e.g. current psychotic symptoms, active substance abuse
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Current primary outcome measure as of 11/10/2022: Impairment in mental health functioning in terms of work, home management, leisure and close relationships, measured with the Work and Social Adjustment Scale (WSAS) at baseline, after 4 weeks of treatment, after 8 weeks of treatment, and 3-month and 6-month follow-up _____ Previous primary outcome measure: Impairment in mental health functioning in terms of work, home management, leisure and close relationships, measured with the Work and Social Adjustment Scale (WSAS) at baseline, after 6 weeks of treatment, after 12 weeks of treatment, and 3-month and 6-month follow up | — |
Secondary
| Measure | Time frame |
|---|---|
| Current secondary outcome measures as of 11/10/2022: 1. Presence and severity of PPS, measured using The Persistent Physical Symptom Checklist (PPSC) at baseline, after 4 weeks of treatment, after 8 weeks of treatment, and 3-month and 6-month follow-up 2. Questionnaire measure of their identified main psychological problem: 2.1. Depression measured using Patient Health Questionnaire-9 (PHQ-9) at baseline, after 4 weeks of treatment, after 8 weeks of treatment, and 3-month and 6-month follow-up 2.2. General anxiety measured using General Anxiety Disorder-7 (GAD-7) at baseline, after 4 weeks of treatment, after 8 weeks of treatment, and 3-month and 6-month follow-up 2.3. Health anxiety measured using Short Health Anxiety Inventory (SHAI) at baseline, after 4 weeks of treatment, after 8 weeks of treatment, and 3-month and 6-month follow-up _____ Previous secondary outcome measures: 1. Presence and severity of PPS, measured using The Persistent Physical Symptom Checklist (PPSC) at baseline, after 6 weeks of treatment, after 12 weeks of treatment, and 3-month and 6-month follow up 2. Questionnaire measure of their identified main psychological problem: 2.1. Depression measured using Patient Health Questionnaire-9 (PHQ-9) at baseline, after 6 weeks of treatment, after 12 weeks of treatment, and 3-month and 6-month follow up 2.2. General anxiety measured using General Anxiety Disorder-7 (GAD-7) at baseline, after 6 weeks of treatment, after 12 weeks of treatment, and 3-month and 6-month follow up 2.3. Health anxiety measured using Short Health Anxiety Inventory (SHAI) at baseline, after 6 weeks of treatment, after 12 weeks of treatment, and 3-month and 6-month follow up | — |
Countries
Iceland
Contacts
Public ContactElín Broddadótir
Outcome results
None listed